{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T19:59:04Z","timestamp":1775678344843,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was supported by BIAL - Portela & Ca, S.A."},{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Opicapone (OPC) is a third-generation, selective peripheral COMT inhibitor that improves peripheral L-DOPA bioavailability and reduces OFF time and end-of-dose motor fluctuations in Parkinson\u2019s disease (PD) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>In this study, we objectively assessed the effects of adding OPC to L-DOPA on bradykinesia in PD through kinematic analysis of finger movements.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We enrolled 20 treated patients with PD and motor fluctuations. Patients underwent two experimental sessions (L-DOPA, L-DOPA\u2009+\u2009OPC), separated by at least 1\u00a0week. In each session, patients were clinically evaluated and underwent kinematic movement analysis of repetitive finger movements at four time points: (i) before their usual morning dose of L-DOPA (T0), (ii) 30\u00a0min (T1), (iii) 1\u00a0h and 30\u00a0min (T2), and (iv) 3\u00a0h and 30\u00a0min after the L-DOPA intake (T3).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Movement velocity and amplitude of finger movements were higher in PD patients during the session with OPC compared to the session without OPC at all the time points tested. Importantly, the variability of finger movement velocity and amplitude across T0\u2013T3 was significantly lower in the L-DOPA\u2009+\u2009OPC than L-DOPA session.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study is the first objective assessment of the effects of adding OPC to L-DOPA on bradykinesia in patients with PD and motor fluctuations. OPC, in addition to the standard dopaminergic therapy, leads to significant improvements in bradykinesia during clinically relevant periods associated with peripheral L-DOPA dynamics, i.e., the OFF state in the morning, delayed-ON, and wearing-OFF periods.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-023-07233-6","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T08:02:19Z","timestamp":1702454539000},"page":"2035-2046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Objective assessment of the effects of opicapone in Parkinson\u2019s disease through kinematic analysis"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-0833","authenticated-orcid":false,"given":"Matteo","family":"Bologna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Colella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Birreci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cannavacciuolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Paparella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Berardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Fabbrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"7233_CR1","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1002\/mds.23875","volume":"26","author":"A Antonini","year":"2011","unstructured":"Antonini A, Martinez-Martin P, Chaudhuri RK et al (2011) Wearing-off scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord Off J Mov Disord Soc 26:2169\u20132175. https:\/\/doi.org\/10.1002\/mds.23875","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"7233_CR2","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/mds.27340","volume":"33","author":"A Antonini","year":"2018","unstructured":"Antonini A, Moro E, Godeiro C, Reichmann H (2018) Medical and surgical management of advanced Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 33:900\u2013908. https:\/\/doi.org\/10.1002\/mds.27340","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"7233_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha J-F et al (2016) Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15:154\u2013165. https:\/\/doi.org\/10.1016\/S1474-4422(15)00336-1","journal-title":"Lancet Neurol"},{"key":"7233_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","volume":"74","author":"AJ Lees","year":"2017","unstructured":"Lees AJ, Ferreira J, Rascol O et al (2017) Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74:197\u2013206. https:\/\/doi.org\/10.1001\/jamaneurol.2016.4703","journal-title":"JAMA Neurol"},{"key":"7233_CR5","doi-asserted-by":"publisher","first-page":"754016","DOI":"10.3389\/fneur.2021.754016","volume":"12","author":"J-F Rocha","year":"2021","unstructured":"Rocha J-F, Ebersbach G, Lees A et al (2021) The added benefit of opicapone when used early in Parkinson\u2019s disease patients with levodopa-induced motor fluctuations: a post-hoc analysis of BIPARK-I and -II. Front Neurol 12:754016. https:\/\/doi.org\/10.3389\/fneur.2021.754016","journal-title":"Front Neurol"},{"key":"7233_CR6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/mds.22480","volume":"24","author":"AJ Espay","year":"2009","unstructured":"Espay AJ, Beaton DE, Morgante F et al (2009) Impairments of speed and amplitude of movement in Parkinson\u2019s disease: a pilot study. Mov Disord Off J Mov Disord Soc 24:1001\u20131008. https:\/\/doi.org\/10.1002\/mds.22480","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"7233_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jns.2016.08.028","volume":"369","author":"M Bologna","year":"2016","unstructured":"Bologna M, Leodori G, Stirpe P et al (2016) Bradykinesia in early and advanced Parkinson\u2019s disease. J Neurol Sci 369:286\u2013291. https:\/\/doi.org\/10.1016\/j.jns.2016.08.028","journal-title":"J Neurol Sci"},{"key":"7233_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/brain\/awz344","volume":"143","author":"M Bologna","year":"2020","unstructured":"Bologna M, Paparella G, Fasano A et al (2020) Evolving concepts on bradykinesia. Brain J Neurol 143:727\u2013750. https:\/\/doi.org\/10.1093\/brain\/awz344","journal-title":"Brain J Neurol"},{"key":"7233_CR9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/mds.870130308","volume":"13","author":"R Agostino","year":"1998","unstructured":"Agostino R, Berardelli A, Curr\u00e0 A et al (1998) Clinical impairment of sequential finger movements in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 13:418\u2013421. https:\/\/doi.org\/10.1002\/mds.870130308","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"7233_CR10","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1111\/ene.14851","volume":"28","author":"G Paparella","year":"2021","unstructured":"Paparella G, Fasano A, Hallett M et al (2021) Emerging concepts on bradykinesia in non-parkinsonian conditions. Eur J Neurol 28:2403\u20132422. https:\/\/doi.org\/10.1111\/ene.14851","journal-title":"Eur J Neurol"},{"key":"7233_CR11","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/mds.23893","volume":"26","author":"AJ Espay","year":"2011","unstructured":"Espay AJ, Giuffrida JP, Chen R et al (2011) Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 26:2504\u20132508. https:\/\/doi.org\/10.1002\/mds.23893","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"7233_CR12","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1093\/brain\/awy155","volume":"141","author":"M Bologna","year":"2018","unstructured":"Bologna M, Guerra A, Paparella G et al (2018) Neurophysiological correlates of bradykinesia in Parkinson\u2019s disease. Brain 141:2432\u20132444. https:\/\/doi.org\/10.1093\/brain\/awy155","journal-title":"Brain"},{"key":"7233_CR13","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/mds.29362","volume":"38","author":"M Bologna","year":"2023","unstructured":"Bologna M, Espay AJ, Fasano A et al (2023) Redefining bradykinesia. Mov Disord Off J Mov Disord Soc 38:551\u2013557. https:\/\/doi.org\/10.1002\/mds.29362","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"7233_CR14","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 30:1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"7233_CR15","doi-asserted-by":"publisher","unstructured":"Movement disorder society task force on rating scales for Parkinson\u2019s disease (2003) The UNIFIED Parkinson\u2019s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord Off J Mov Disord Soc 18:738\u2013750 https:\/\/doi.org\/10.1002\/mds.10473","DOI":"10.1002\/mds.10473"},{"key":"7233_CR16","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord Off J Mov Disord Soc 23:2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"7233_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10072-012-1112-z","volume":"34","author":"A Antonini","year":"2013","unstructured":"Antonini A, Abbruzzese G, Ferini-Strambi L et al (2013) Validation of the Italian version of the Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 34:683\u2013687. https:\/\/doi.org\/10.1007\/s10072-012-1112-z","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"key":"7233_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695\u2013699. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x","journal-title":"J Am Geriatr Soc"},{"key":"7233_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT, Ward CH, Mendelson M et al (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561\u2013571","journal-title":"Arch Gen Psychiatry"},{"key":"7233_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/brain\/awab257","volume":"145","author":"A Guerra","year":"2022","unstructured":"Guerra A, Colella D, Giangrosso M et al (2022) Driving motor cortex oscillations modulates bradykinesia in Parkinson\u2019s disease. Brain J Neurol 145:224\u2013236. https:\/\/doi.org\/10.1093\/brain\/awab257","journal-title":"Brain J Neurol"},{"key":"7233_CR21","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/mds.23740","volume":"26","author":"DA Heldman","year":"2011","unstructured":"Heldman DA, Giuffrida JP, Chen R et al (2011) The modified bradykinesia rating scale for Parkinson\u2019s disease: reliability and comparison with kinematic measures. Mov Disord Off J Mov Disord Soc 26:1859\u20131863. https:\/\/doi.org\/10.1002\/mds.23740","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"7233_CR22","doi-asserted-by":"publisher","first-page":"100083","DOI":"10.1016\/j.prdoa.2020.100083","volume":"4","author":"J Greenwood","year":"2021","unstructured":"Greenwood J, Pham H, Rey J (2021) Opicapone: a third generation COMT inhibitor. Clin Park Relat Disord 4:100083. https:\/\/doi.org\/10.1016\/j.prdoa.2020.100083","journal-title":"Clin Park Relat Disord"},{"key":"7233_CR23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/bcp.12081","volume":"76","author":"JF Rocha","year":"2013","unstructured":"Rocha JF, Almeida L, Falc\u00e3o A et al (2013) Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 76:763. https:\/\/doi.org\/10.1111\/bcp.12081","journal-title":"Br J Clin Pharmacol"},{"key":"7233_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/WNF.0000000000000184","volume":"39","author":"M Bologna","year":"2016","unstructured":"Bologna M, Latorre A, Di Biasio F et al (2016) The effect of L-Dopa\/carbidopa intestinal gel in Parkinson disease assessed using neurophysiologic techniques. Clin Neuropharmacol 39:302\u2013305. https:\/\/doi.org\/10.1097\/WNF.0000000000000184","journal-title":"Clin Neuropharmacol"},{"key":"7233_CR25","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/mds.29193","volume":"37","author":"JJ Ferreira","year":"2022","unstructured":"Ferreira JJ, Poewe W, Rascol O et al (2022) Effect of opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 37:2272\u20132283. https:\/\/doi.org\/10.1002\/mds.29193","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"7233_CR26","doi-asserted-by":"publisher","unstructured":"Guerra A, D\u2019Onofrio V, Ferreri F et al (2023) Objective measurement versus clinician-based assessment for Parkinson\u2019s disease. Expert Rev Neurother 23:689\u2013702. https:\/\/doi.org\/10.1080\/14737175.2023.2229954","DOI":"10.1080\/14737175.2023.2229954"},{"key":"7233_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3233\/JPD-223256","volume":"13","author":"S Williams","year":"2023","unstructured":"Williams S, Wong D, Alty JE, Relton SD (2023) Parkinsonian hand or clinician\u2019s eye? Finger tap bradykinesia interrater reliability for 21 movement disorder experts. J Park Dis 13:525\u2013536. https:\/\/doi.org\/10.3233\/JPD-223256","journal-title":"J Park Dis"},{"key":"7233_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/mds.22343","volume":"24","author":"RA Hauser","year":"2009","unstructured":"Hauser RA, Panisset M, Abbruzzese G et al (2009) Double-blind trial of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa in early Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 24:541\u2013550. https:\/\/doi.org\/10.1002\/mds.22343","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"7233_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12883-022-02602-8","volume":"22","author":"KR Chaudhuri","year":"2022","unstructured":"Chaudhuri KR, Odin P, Ferreira JJ et al (2022) Opicapone versus placebo in the treatment of Parkinson\u2019s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial. BMC Neurol 22:88. https:\/\/doi.org\/10.1186\/s12883-022-02602-8","journal-title":"BMC Neurol"},{"key":"7233_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00702-023-02623-8","volume":"130","author":"M Regensburger","year":"1996","unstructured":"Regensburger M, Ip CW, Kohl Z et al (1996) (2023) Clinical benefit of MAO-B and COMT inhibition in Parkinson\u2019s disease: practical considerations. J Neural Transm Vienna Austria 130:847\u2013861. https:\/\/doi.org\/10.1007\/s00702-023-02623-8","journal-title":"J Neural Transm Vienna Austria"},{"key":"7233_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40262-012-0024-7","volume":"52","author":"L Almeida","year":"2013","unstructured":"Almeida L, Rocha JF, Falc\u00e3o A et al (2013) Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet 52:139\u2013151. https:\/\/doi.org\/10.1007\/s40262-012-0024-7","journal-title":"Clin Pharmacokinet"},{"key":"7233_CR32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/mds.28322","volume":"36","author":"A Takeda","year":"2021","unstructured":"Takeda A, Takahashi R, Tsuboi Y et al (2021) Randomized, controlled study of opicapone in Japanese Parkinson\u2019s patients with motor fluctuations. Mov Disord Off J Mov Disord Soc 36:415\u2013423. https:\/\/doi.org\/10.1002\/mds.28322","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"7233_CR33","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3390\/cells11091511","volume":"11","author":"T M\u00fcller","year":"2022","unstructured":"M\u00fcller T, Schlegel E, Zingler S, Thiede HM (2022) Effects of one-day application of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa\/opicapone in Parkinson\u2019s disease patients. Cells 11:1511. https:\/\/doi.org\/10.3390\/cells11091511","journal-title":"Cells"},{"key":"7233_CR34","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/cpdd.217","volume":"5","author":"J-F Rocha","year":"2016","unstructured":"Rocha J-F, Ferreira JJ, Falc\u00e3o A et al (2016) Effect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor response in patients with Parkinson disease. Clin Pharmacol Drug Dev 5:232\u2013240. https:\/\/doi.org\/10.1002\/cpdd.217","journal-title":"Clin Pharmacol Drug Dev"},{"key":"7233_CR35","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/bcp.13156","volume":"83","author":"J-F Rocha","year":"2017","unstructured":"Rocha J-F, Sicard \u00c9, Fauchoux N et al (2017) Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics. Br J Clin Pharmacol 83:540\u2013553. https:\/\/doi.org\/10.1111\/bcp.13156","journal-title":"Br J Clin Pharmacol"},{"key":"7233_CR36","doi-asserted-by":"publisher","first-page":"106137","DOI":"10.1016\/j.nbd.2023.106137","volume":"182","author":"A Guerra","year":"2023","unstructured":"Guerra A, Colella D, Cannavacciuolo A et al (2023) Short-term plasticity of the motor cortex compensates for bradykinesia in Parkinson\u2019s disease. Neurobiol Dis 182:106137. https:\/\/doi.org\/10.1016\/j.nbd.2023.106137","journal-title":"Neurobiol Dis"},{"key":"7233_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29615","author":"M Conti","year":"2023","unstructured":"Conti M, Guerra A, Pierantozzi M et al (2023) Band-specific altered cortical connectivity in early Parkinson\u2019s disease and its clinical correlates. Mov Disord Off J Mov Disord Soc. https:\/\/doi.org\/10.1002\/mds.29615","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"7233_CR38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/bs.pbr.2020.02.002","volume":"252","author":"P Petersson","year":"2020","unstructured":"Petersson P, K\u00fchn AA, Neumann W-J, Fuentes R (2020) Basal ganglia oscillations as biomarkers for targeting circuit dysfunction in Parkinson\u2019s disease. Prog Brain Res 252:525\u2013557. https:\/\/doi.org\/10.1016\/bs.pbr.2020.02.002","journal-title":"Prog Brain Res"},{"key":"7233_CR39","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.parkreldis.2014.02.022","volume":"20","author":"DA Heldman","year":"2014","unstructured":"Heldman DA, Espay AJ, LeWitt PA, Giuffrida JP (2014) Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson\u2019s disease. Parkinsonism Relat Disord 20:590\u2013595. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.02.022","journal-title":"Parkinsonism Relat Disord"},{"key":"7233_CR40","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s40120-022-00371-7","volume":"11","author":"JJ Ferreira","year":"2022","unstructured":"Ferreira JJ, Poewe W, Rascol O et al (2022) Opicapone as an add-on to levodopa in patients with Parkinson\u2019s disease without motor fluctuations: rationale and design of the phase III, double-blind, randomised, placebo-controlled EPSILON trial. Neurol Ther 11:1409\u20131425. https:\/\/doi.org\/10.1007\/s40120-022-00371-7","journal-title":"Neurol Ther"}],"updated-by":[{"DOI":"10.1007\/s10072-023-07294-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000}}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07233-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-07233-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07233-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T04:38:16Z","timestamp":1713242296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-07233-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["7233"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-07233-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10072-023-07294-7","asserted-by":"object"}]},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"assertion":[{"value":"10 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10072-023-07294-7","URL":"https:\/\/doi.org\/10.1007\/s10072-023-07294-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the local Ethics Committee (Sapienza University of Rome). The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All participants provided informed consent to the experimental procedures and for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Angelo Antonini has received compensation for consultancy and speaker-related activities from UCB, Britannia, AbbVie, Zambon, Bial, Ever Pharma, Theravance Biopharma, Roche, General Electric, and Medscape. He receives research support from Chiesi Pharmaceuticals, Lundbeck, Bial, Movement Disorder Society, Horizon2020 Grant 825785, Horizon2020 Grant 101016902, and Ministry of Education University and Research (MIUR) Grant ARS01_01081. Matteo Bologna, Andrea Guerra, Donato Colella, Daniele Birreci, Davide Costa, Antonio Cannavacciuolo, Luca Angelini, Giulia Paparella, Alfredo Berardelli, and Giovanni Fabbrini declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}